Elsiglutide: Phase IIa started

Helsinn began a double-blind, placebo-controlled, European Phase IIa trial evaluating 24 mg subcutaneous elsiglutide once daily for 4 days in 138 patients with colorectal cancer receiving 5-fluorourac...